Multiple Manufacturers

ISTODAX

Manufacturer:

Multiple Manufacturers

Istodax HCPCS:

J9319

HCPCS Code Descriptor:

Injection, romidepsin, lyophilized, 0.1 mg

Category:

J Code

Istodax NDCs:

59572-0984-01, 63323-0926-88

Primary Type:

Oncology

Generic/Specialty Status:

Multi-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Istodax:

ISTODAX is an Oncology drug manufactured by Celgene and administered via the Intravenous route of administration. The J Code: J9319 is aligned to the drug ISTODAX.

ISTODAX is a histone deacetalyse (HDAC) inhibitor that is commonly used to treat cutaneous T-cell lymphoma (CTCL). It is indicated for use in adult patients who have already received a systemic treatment for their CTCL. ISTODAX (J9319) works by causing a buildup of acetylated histones, compounds responsible for modulating gene expression. This causes cell cycle arrest and apoptosis in cancer cells. Patient assistance for this medication can be found through Bristol Meyers Squibb.

ACCESS PRICING AND MORE BY REGISTERING

J9319 Added Date:

October 1, 2021

J9319 Effective Date:

October 1, 2021

J9319 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Istodax billing and coding information.
Istodax patient assistance information can be found through Bristol Myers Squibb Access Support at the URL: https://www.bmsaccesssupport.bmscustomerconnect.com/patient
ISTODAX prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for ISTODAX. Please check back in a few weeks.